136 related articles for article (PubMed ID: 20051608)
1. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
[TBL] [Abstract][Full Text] [Related]
2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
[TBL] [Abstract][Full Text] [Related]
4. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
6. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
7. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
Zettl H; Schubert-Zsilavecz M; Siebert CD
Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
[No Abstract] [Full Text] [Related]
8. Ondansetron to prevent vomiting after cancer chemotherapy.
Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
[No Abstract] [Full Text] [Related]
9. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
[TBL] [Abstract][Full Text] [Related]
10. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
[TBL] [Abstract][Full Text] [Related]
11. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
12. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy-induced emesis and serotonin antagonists].
Jantunen I; Johansson R
Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
[No Abstract] [Full Text] [Related]
14. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
15. Migraine-type headaches in children receiving chemotherapy and ondansetron.
Khan RB
J Child Neurol; 2002 Nov; 17(11):857-8. PubMed ID: 12585731
[TBL] [Abstract][Full Text] [Related]
16. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron.
Pivot D; Javot L; Swiegot D; Petitpain N; Spaëth D; Trechot P
Therapie; 2013; 68(6):409-10. PubMed ID: 24246123
[No Abstract] [Full Text] [Related]
17. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
18. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
Anastasia PJ
Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
[TBL] [Abstract][Full Text] [Related]
20. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig P
J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
